KUKJEON PHARMACEUTICAL Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	46,824	10,992	21,546	19,099
Short-Term Investments	-	15,000	45,000	20,160
Trading Asset Securities	-	38,840	28,425	-
Cash & Short-Term Investments	46,824	64,833	94,971	39,259
Cash Growth	-27.78%	-31.73%	141.91%	-
Accounts Receivable	28,779	26,850	21,923	20,015
Other Receivables	66.66	1,964	867.93	194.62
Receivables	29,255	29,065	23,403	20,409
Inventory	26,798	27,563	20,209	16,207
Prepaid Expenses	538.53	494.91	246.48	143.8
Other Current Assets	1,773	2,036	4,064	896.09
Total Current Assets	105,189	123,992	142,893	76,915
Property, Plant & Equipment	87,360	86,060	46,118	24,026
Long-Term Investments	5,322	4,364	3,173	3,493
Goodwill	420.39	420.39	420.39	-
Other Intangible Assets	908.17	971	903.51	422.37
Long-Term Deferred Tax Assets	2,185	1,964	-	794.9
Long-Term Deferred Charges	3,500	-	-	-
Other Long-Term Assets	7,169	7,090	2,379	517.79
Total Assets	212,273	225,102	196,097	106,989
Accounts Payable	17,833	11,693	9,474	10,989
Accrued Expenses	359.99	289.73	178.99	83.02
Short-Term Debt	8,560	15,224	7,883	5,133
Current Portion of Long-Term Debt	31,819	36,802	26,015	1,457
Current Portion of Leases	274.88	236.17	147.15	124.88
Current Income Taxes Payable	-	-	-	1,057
Current Unearned Revenue	-	35.16	-	-
Other Current Liabilities	29,729	35,542	26,993	3,007
Total Current Liabilities	88,576	99,823	70,691	21,852
Long-Term Debt	24,035	26,183	25,091	942.84
Long-Term Leases	622.23	334.14	202.84	193.97
Long-Term Deferred Tax Liabilities	10.45	10.45	1,365	-
Other Long-Term Liabilities	1,529	1,296	6,425	849.76
Total Liabilities	114,774	127,646	103,774	23,838
Common Stock	4,907	4,907	4,907	4,907
Additional Paid-In Capital	62,139	62,386	62,386	62,397
Retained Earnings	30,375	29,129	24,305	15,848
Treasury Stock	-1.16	-1.16	-1.16	-1.16
Comprehensive Income & Other	-0	0	0	0
Total Common Equity	97,420	96,422	91,597	83,150
Minority Interest	79.38	1,035	725.74	-
Shareholders' Equity	97,499	97,456	92,323	83,150
Total Liabilities & Equity	212,273	225,102	196,097	106,989
Total Debt	65,312	78,780	59,339	7,852
Net Cash (Debt)	-18,488	-13,947	35,632	31,407
Net Cash Growth	-	-	13.45%	-
Net Cash Per Share	-376.77	-284.24	695.44	712.02
Filing Date Shares Outstanding	49.07	49.07	49.07	49.07
Total Common Shares Outstanding	49.07	49.07	49.07	49.07
Working Capital	16,613	24,169	72,202	55,063
Book Value Per Share	1985.36	1965.01	1866.70	1694.56
Tangible Book Value	96,091	95,030	90,274	82,728
Tangible Book Value Per Share	1958.28	1936.66	1839.72	1685.95
Land	20,224	19,837	15,613	3,997
Buildings	38,047	36,673	11,300	8,252
Machinery	30,295	22,297	11,051	7,554
Construction In Progress	624.1	6,407	13,388	9,214

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.